Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Ellyn Witt

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Archives of Otolaryngology--Head & Neck Surgery|December 22, 2010
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancerKent W Mouw, Daniel J Haraf, Kerstin M Stenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancerTanguy Y Seiwert, Daniel J Haraf, Ezra E W Cohen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano, Everett E Vokes, Joseph K Salama, et al.
Head & Neck|April 3, 2009
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapyEzra E W Cohen, Joshua Baru, Dezheng Huo, et al.
Oral Oncology|May 25, 2012
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapyKent W Mouw, Abhishek A Solanki, Kerstin M Stenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancerDaniel J Haraf, Fred R Rosen, Kerstin Stenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trialEzra E W Cohen, Daniel J Haraf, Marcy A List, et al.
Cancer|June 15, 2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiationKevin S Choe, Daniel J Haraf, Abhishek Solanki, et al.
International Journal of Oncology|April 6, 2006
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directionsMichael T Milano, Everett E Vokes, Johnny Kao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancerFred R Rosen, Daniel J Haraf, Merrill S Kies, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Archives of Otolaryngology--Head & Neck Surgery|December 22, 2010
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancerKent W Mouw, Daniel J Haraf, Kerstin M Stenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancerTanguy Y Seiwert, Daniel J Haraf, Ezra E W Cohen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano, Everett E Vokes, Joseph K Salama, et al.
Head & Neck|April 3, 2009
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapyEzra E W Cohen, Joshua Baru, Dezheng Huo, et al.
Oral Oncology|May 25, 2012
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapyKent W Mouw, Abhishek A Solanki, Kerstin M Stenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancerDaniel J Haraf, Fred R Rosen, Kerstin Stenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trialEzra E W Cohen, Daniel J Haraf, Marcy A List, et al.
Cancer|June 15, 2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiationKevin S Choe, Daniel J Haraf, Abhishek Solanki, et al.
International Journal of Oncology|April 6, 2006
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directionsMichael T Milano, Everett E Vokes, Johnny Kao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancerFred R Rosen, Daniel J Haraf, Merrill S Kies, et al.
Pageof 3